Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease

X
Trial Profile

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prasugrel (Primary)
  • Indications Embolism and thrombosis; Sickle cell anaemia; Vaso-occlusive crisis
  • Focus Registrational; Therapeutic Use
  • Acronyms DOVE; TADO
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 27 Jul 2020 This trial is completed in UK (Global End Date: 16 Sep 2015), according to European Clinical Trials Database record.
    • 12 Dec 2017 Results of evaluation of candidate gene variants and impact of these variants on prasugrel treatment response presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2016 Results published in the Thrombosis and Haemostasis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top